Stephan A. Grupp
Stephan A. Grupp
Professor of Pediatrics, University of Pennsylvania School of Medicine
Verified email at email.chop.edu
Title
Cited by
Cited by
Year
Chimeric antigen receptor T cells for sustained remissions in leukemia
SL Maude, N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, ...
New England Journal of Medicine 371 (16), 1507-1517, 2014
38342014
Chimeric antigen receptor–modified T cells for acute lymphoid leukemia
SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, ...
New England Journal of Medicine 368 (16), 1509-1518, 2013
30062013
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June
Science translational medicine 3 (95), 95ra73-95ra73, 2011
24102011
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, ...
New England Journal of Medicine 378 (5), 439-448, 2018
19962018
Current concepts in the diagnosis and management of cytokine release syndrome
DW Lee, R Gardner, DL Porter, CU Louis, N Ahmed, M Jensen, SA Grupp, ...
Blood 124 (2), 188-195, 2014
16042014
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
AL Yu, AL Gilman, MF Ozkaynak, WB London, SG Kreissman, HX Chen, ...
New England Journal of Medicine 363 (14), 1324-1334, 2010
13752010
Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species
MA Goodell, M Rosenzweig, H Kim, DF Marks, MA DeMaria, G Paradis, ...
Nature medicine 3 (12), 1337-1345, 1997
13341997
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
DL Porter, WT Hwang, NV Frey, SF Lacey, PA Shaw, AW Loren, A Bagg, ...
Science translational medicine 7 (303), 303ra139-303ra139, 2015
11642015
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
MC Milone, JD Fish, C Carpenito, RG Carroll, GK Binder, D Teachey, ...
Molecular therapy 17 (8), 1453-1464, 2009
10232009
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
MV Maus, SA Grupp, DL Porter, CH June
Blood 123 (17), 2625-2635, 2014
7702014
Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy
E Sotillo, DM Barrett, KL Black, A Bagashev, D Oldridge, G Wu, ...
Cancer discovery 5 (12), 1282-1295, 2015
6982015
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
KG Roberts, RD Morin, J Zhang, M Hirst, Y Zhao, X Su, SC Chen, ...
Cancer cell 22 (2), 153-166, 2012
6842012
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
DW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ...
Biology of Blood and Marrow Transplantation 25 (4), 625-638, 2019
6522019
Managing cytokine release syndrome associated with novel T cell-engaging therapies
SL Maude, D Barrett, DT Teachey, SA Grupp
Cancer journal (Sudbury, Mass.) 20 (2), 119, 2014
5892014
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
SL Maude, DT Teachey, DL Porter, SA Grupp
Blood 125 (26), 4017-4023, 2015
5692015
Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
DT Teachey, SF Lacey, PA Shaw, JJ Melenhorst, SL Maude, N Frey, ...
Cancer discovery 6 (6), 664-679, 2016
5642016
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
DT Teachey, SR Rheingold, SL Maude, G Zugmaier, DM Barrett, AE Seif, ...
Blood 121 (26), 5154-5157, 2013
4722013
Chimeric antigen receptor therapy for cancer
DM Barrett, N Singh, DL Porter, SA Grupp, CH June
Annual review of medicine 65, 333-347, 2014
3572014
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, ...
The Journal of clinical investigation 126 (10), 3814-3826, 2016
3552016
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells
S Gill, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, ...
Blood, The Journal of the American Society of Hematology 123 (15), 2343-2354, 2014
3482014
The system can't perform the operation now. Try again later.
Articles 1–20